$28MSeries C, 29 October 2025
Series C funds commercial expansion, clinical evidence and new indications for the FLEX VP System.
- Amount
- $28M
- Stage
- Series C
- Announced
- 29 October 2025
- Lead
- S3 Ventures
- Other investors
- Endeavour Vision
- Use of funds
- Series C funds commercial expansion, clinical evidence and new indications for the FLEX VP System.
- Checked
- Announced by the company
- Sources
- VentureMed closes $28M Series C (date approx) endeavourvision.com
VentureMed closes $28M Series C (date approx) pulse2.com